Studies further suggest that DNMT inhibitors, targeting aberrant DNMT activity, offer therapeutic potential in cancer treatment by reactivating silenced TSGs and restoring normal gene expression profiles (Van Tongelen et al. 2017). Here, DNMT1 is linked to cancer.